Sino Biopharm's rovadicitinib shows promise in graft-versus-host disease

Sino Biopharmaceutical Limited (HKEX: 1177) announced positive preclinical and Phase Ib clinical study results for rovadicitinib in treating acute graft-versus-host disease (aGVHD) at the 2025 EHA Congress. The study showed an overall response rate (ORR) of 84.6% at 28 days, a median response time of 4 days, and a 12-month overall survival rate of 92.3%. Rovadicitinib, a selective JAK1/2 and ROCK1/2 inhibitor, targets multiple pathways involved in aGVHD and offers a potentially effective alternative for steroid-refractory (SR) aGVHD patients. Within 56 days, 38.5% of patients completely discontinued steroid use in the rovadicitinib trial. A Phase III clinical trial of rovadicitinib for treating chronic graft-versus-host disease (cGVHD) is underway.